Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 4 of 3330
Next
>>
>
76 to 100 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
184A1	NM	Basal	AS-252424	PI3K	PI3K	6.67	uM	12509.165	0.5506	0.3443	1.5022
184A1	NM	Basal	Baicalein	Lipoxygenase	Metabolism	0.000427	uM	5895.073	1.0365	1.0503	1.4431
184A1	NM	Basal	Baicalein	Lipoxygenase	Metabolism	0.00213	uM	5895.073	1.0337	1.0465	1.4431
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		0.267	uM	9047.132	0.9995	0.9985	0.6985
184A1	NM	Basal	5-FU	TYMS	TYMS	3840	uM	9047.017	0.1150	-0.8459	0.8440
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	0.000171	uM	12509.165	0.9871	0.9828	1.5022
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.00128	uM	9047.037	1.0758	1.2981	0.5262
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		0.000427	uM	9047.132	1.0270	1.0778	0.6985
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	0.0213	uM	12509.165	0.5575	0.3556	1.5022
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	0.533	uM	12509.165	0.3318	-0.0404	1.5022
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	0.107	uM	12509.165	0.3373	-0.0298	1.5022
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		0.00213	uM	9047.132	0.9693	0.9128	0.6985
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	66.7	uM	12509.165	0.0097	-0.9088	1.5022
184A1	NM	Basal	Baicalein	Lipoxygenase	Metabolism	33.3	uM	5895.073	0.8615	0.8038	1.4431
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.000256	uM	9047.037	0.9096	0.6705	0.5262
184A1	NM	Basal	AG1024	IGF1R	RTK	0.000427	uM	5894.066	1.0325	1.0430	1.5027
184A1	NM	Basal	Bortezomib	Proteasome	Proteasome	0.000427	uM	5894.074	1.0584	1.0796	1.4541
184A1	NM	Basal	AG1024	IGF1R	RTK	0.0000853	uM	5894.066	1.0769	1.1011	1.5027
184A1	NM	Basal	Bortezomib	Proteasome	Proteasome	0.00213	uM	5894.074	1.0465	1.0635	1.4541
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		1.33	uM	9047.132	0.9661	0.9036	0.6985
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.8	uM	9047.037	0.4311	-0.5959	0.5262
184A1	NM	Basal	17-AAG	HSP90	HSP90	4	uM	9047.037	0.4226	-0.6108	0.5262
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.032	uM	9047.037	0.4452	-0.5704	0.5262
184A1	NM	Basal	Bortezomib	Proteasome	Proteasome	0.000427	uM	5895.074	1.0527	1.0937	1.1218
184A1	NM	Basal	Bortezomib	Proteasome	Proteasome	167	uM	5894.074	0.0861	-0.6297	1.4541

|<
<<
Previous
Page 4 of 3330
Next
>>
>
76 to 100 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)